Evaxion Biotech has concluded an agreement with European Investment Bank (EIB) to convert EUR 3,5 million of the EIB loan totaling EUR 7 million into equity through the purchase of warrants at USD 4,87 per share, a premium of 89 percent. The transaction increases Evaxion's equity by USD 4,1 million, reduces debt and improves cash flow, strengthening the company's financial flexibility for the development of AI-powered vaccines.
|
Published July 11, 2025
Evaxion converts debt of EUR 3,5 million
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account